NASDAQ Composite

Quotazioni in diretta

Assistente personale

MRK Merck and Co Inc

126,02

0,79 (0,63%)

Ultimo aggiornamento: 21:27:12

Dati in Delay di 15 minuti

Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer

To read the full story on Seeking Alpha, click here.

Grafico Azioni Merck (NYSE:MRK)
Storico
Da Mar 2024 a Apr 2024

Clicca qui per i Grafici di Merck

Grafico Azioni Merck (NYSE:MRK)
Storico
Da Apr 2023 a Apr 2024

Clicca qui per i Grafici di Merck

Notizie Merck and Co Inc - MRK

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Venerdì 19 Aprile 2024 (9 ore fa) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Mercoledì 10 Aprile 2024 (1 settimana fa) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Giovedì 4 Aprile 2024 (2 settimane fa) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Mercoledì 3 Aprile 2024 (2 settimane fa) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Lunedì 1 Aprile 2024 (3 settimane fa) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Giovedì 28 Marzo 2024 (3 settimane fa) • Business Wire

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Mercoledì 27 Marzo 2024 (3 settimane fa) • IH Market News

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Martedì 26 Marzo 2024 (3 settimane fa) • Business Wire

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Giovedì 21 Marzo 2024 (4 settimane fa) • Business Wire

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Martedì 19 Marzo 2024 (1 mese fa) • Business Wire

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
Venerdì 15 Marzo 2024 (1 mese fa) • PR Newswire (US)

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Venerdì 15 Marzo 2024 (1 mese fa) • Business Wire

Più Merck and Co Inc Articoli Notizie

Intesa Sanpaolo

ST Microelectronics

Banca Monte Dei Paschi D...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea